Form 4: Amgen Executive Reports Routine Stock Disposition

Amgen SVP of Business Development Rachna Khosla disposed of 225 shares to cover tax obligations related to equity vesting.

Summary

• Rachna Khosla, SVP of Business Development at Amgen, executed a transaction on May 2, 2026.
• The transaction involved the disposition of 225 shares of common stock in total.
• 117 shares were disposed of at a price of $329.82.
• 108 shares were disposed of at a price of $329.82.
• The total remaining beneficial ownership following these transactions is 8,066 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax obligations rather than a strategic market move.

Positives

• The transaction was a routine tax withholding event rather than a discretionary market sale.

Negatives

• Reduction in the reporting person's direct equity stake in the company.

Risks

• None identified; this is a standard regulatory filing for executive compensation tax compliance.

Future Outlook

Not applicable; this is a historical record of an insider transaction.

Industry Context

StockSavvy.ai notes that tax-related share withholding is a standard practice for corporate executives upon the vesting of restricted stock units and does not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices observed across the S&P 500 and the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax withholding.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Executive Compensation, Biotech